Circio

Description

Circio develops circular RNA and immunotherapy medicines, including circVec AAV gene therapy work that uses circular RNA to enhance expression in target tissues for genetic disease applications.

Circio is located in the Stockholm ecosystem.

Related

• SpliceBioSpliceBio builds protein splicing–based genetic medicines and develops therapeutics for diseases caused by mutations in large genes,…
• Oxford BiomedicaOxford Biomedica provides end-to-end CDMO services for cell and gene therapy clients, using lentivirus, AAV, and other viral vectors to…
• SyngensysSyngensys develops synthetic gene promoters using transcriptional landscape analysis, computational design, selection, and validation to…
• Phlox TherapeuticsPhlox Therapeutics develops precision RNA-based therapies to treat rare genetic cardiomyopathies, creating therapeutic candidates and…
• Hansa BiopharmaHansa Biopharma develops immunomodulating antibody-cleaving enzyme therapies that target and inactivate IgG antibodies, inhibiting…
• STORM TherapeuticsSTORM Therapeutics develops small molecule inhibitors of RNA-modifying enzymes, including STC-15, a METTL3 inhibitor in clinical…
• AAsgard TherapeuticsAsgard Therapeutics develops AT-108, an off-the-shelf gene therapy using direct cell reprogramming to activate professional…
• ThelperThelper develops antiviral antibody–drug conjugates that target a virally encoded biomarker abundantly expressed in aggressive, metastatic…
• CPTxCPTx develops in vivo CAR-T genetic medicines using an immune-silent ssDNA platform and non-viral lipid nanoparticle delivery to encode…